Literature DB >> 3066528

Human prorenin: pathophysiology and clinical implications.

F H Derkx1, M A Schalekamp.   

Abstract

Renin and prorenin, the latter after conversion to renin, are usually measured by indirect RIA using antibodies against angiotensin I. They can now also be measured by direct RIA using monoclonal antibodies reacting with total immunoreactive renin (renin plus prorenin) or with renin alone. Results of measurements in renal and peripheral venous plasma indicate that normally a large proportion of prorenin in plasma is of renal origin and they support the concept of separate pathways for prorenin and renin secretion by the JG-cells. Acute stimulation causes a prompt increase of plasma renin without any change in prorenin. During chronic stimulation both renin and prorenin are increased, in such a way that the ratio between the two is higher the stronger the stimulus. Thus, with acute stimulation only the release of stored renin appears to be increased (regulated pathway), whereas during chronic stimulation the synthesis and secretion of prorenin are also (constitutive pathway). During pregnancy, in the early luteal phase of the menstrual cycle and after ovarian hyperstimulation with gonadotropins, a normal or somewhat elevated plasma level of renin is associated with a disproportionally high level of prorenin. This is an indication of extrarenal production of prorenin and in these conditions the ovary, probably corpus luteum, seems to be the main source. In most patients with renin-producing tumors plasma prorenin is also disproportionally high. In diabetes mellitus complicated by micro-angiopathy plasma prorenin is also elevated whereas renin is normal or even low. In diabetics with end-stage nephropathy we found no significant veno-arterial difference in prorenin across the kidneys, despite high circulating prorenin and a very low blood flow through these kidneys, suggesting that also in these patients part of the increased prorenin in plasma is of extrarenal origin. Thus, measurements of prorenin in plasma in various pathological conditions may contribute to a better understanding of the physiological role of the renal and extrarenal renin-angiotensin systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3066528

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  10 in total

1.  Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay.

Authors:  H Yokota; F Mori; K Kai; T Nagaoka; N Izumi; A Takahashi; T Hikichi; A Yoshida; F Suzuki; Y Ishida
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 2.  Possible contribution of (pro)renin receptor to development of gestational diabetes mellitus.

Authors:  Kanako Bokuda; Atsuhiro Ichihara
Journal:  World J Diabetes       Date:  2014-12-15

3.  Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.

Authors:  Huifang Cheng; Xiaofeng Fan; Gilbert W Moeckel; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2011-07       Impact factor: 10.121

Review 4.  New pharmacological treatments for improving renal outcomes in diabetes.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

5.  Renin-like immunoreactivity in human placenta and fetal membranes.

Authors:  M Hanssens; L Vercruysse; L Verbist; R Pijnenborg; M J Keirse; F A Van Assche
Journal:  Histochem Cell Biol       Date:  1995-12       Impact factor: 4.304

6.  Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease.

Authors:  Kazu Hamada; Yoshinori Taniguchi; Yoshiko Shimamura; Kosuke Inoue; Koji Ogata; Masayuki Ishihara; Taro Horino; Shimpei Fujimoto; Takashi Ohguro; Yukio Yoshimoto; Mika Ikebe; Kenji Yuasa; Eri Hoshino; Tatsuo Iiyama; Atsuhiro Ichihara; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2013-04-06       Impact factor: 2.801

7.  First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.

Authors:  Konstantinos Savvatis; Dirk Westermann; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Integr Blood Press Control       Date:  2010-12-01

8.  Determinants of Maternal Renin-Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts.

Authors:  Rosalieke E Wiegel; A H Jan Danser; Régine P M Steegers-Theunissen; Joop S E Laven; Sten P Willemsen; Valerie L Baker; Eric A P Steegers; Frauke von Versen-Höynck
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

Review 9.  The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

Authors:  Paolo Verdecchia; Fabio Angeli; Giovanni Mazzotta; Giorgio Gentile; Gianpaolo Reboldi
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Involvement of (pro)renin receptor in the glomerular filtration barrier.

Authors:  Atsuhiro Ichihara; Mariyo Sakoda; Asako Kurauchi-Mito; Yuki Kaneshiro; Hiroshi Itoh
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.